Preferentially Expressed Antigen of Melanoma (PRAME) is a premier cancer-testis antigen (CTA) that has emerged as a high-value target in oncology. Because PRAME is an intracellular protein, therapeutic strategies bypass traditional monoclonal antibodies. Instead, development focuses on TCR-T cell therapies, TCR-bispecifics (ImmTACs), and TCR-like (TCRm) monoclonal antibodies that target the PRAME peptide presented by HLA-A*02:01. This landscape requires highly specialized, sequence-verified reagents to validate MHC-peptide presentation, TCR binding affinity, and off-target cross-reactivity.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PRAME drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HLA-A*02:01-PRAME (VLDGLDVLL) Complex / Recombinant PRAME Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PRAME Products |
| Gene Delivery | PRAME / HLA-A*02:01 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PRAME Products |
| Benchmark Ab | Anti-PRAME TCR-like Recombinant Antibody Recombinant positive control for peptide-MHC recognition. |
View PRAME Products |
| Validator | PRAME siRNA Set For knockdown verification. |
View PRAME Products |
| Related Target A | MAGE-A4 Co-expressed cancer-testis antigen; key target for TCR-T cell therapies in solid tumors. |
View MAGEA4 Products |
| Related Target B | NY-ESO-1 Synergistic pathway target; frequently co-screened in multi-antigen cancer vaccine and TCR-T programs. |
View NY-ESO-1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Peptide-MHC conformation stability | Biotinylated HLA-A*02:01-PRAME monomer assembled with high-purity synthetic peptide; strictly sequence verified. |
| Off-target cross-reactivity screening | Homolog panel of HLA-A*02:01 complexes presenting decoy self-peptides to rule out off-target TCR binding. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PRAME R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PRAME therapeutics is intensifying, with major players shifting focus from traditional mAbs to TCR-based modalities (TCR-T and ImmTACs) and TCR-like antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting solid tumors with high heterogeneity by combining PRAME-targeted therapies with checkpoint inhibitors or developing multi-specific TCRs to bypass HLA down-regulation and antigen escape.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-Bispecific (ImmTAC) | Immunocore (IMC-F106C) | Melanoma, Ovarian Cancer, NSCLC | Affinity determination (Requires stable HLA-A*02:01-PRAME monomers) |
| TCR-T Cell Therapy | Adaptimmune, GSK, Affini-T | Synovial Sarcoma, Solid Tumors | Transduction validation (Need Lentivirus for stable HLA/PRAME expression) |
| TCR-like (TCRm) Antibody | BioNTech, Eureka Therapeutics | Leukemia, Solid Tumors | Specificity validation (Need target-expressing stable cell lines) |